ID: ALA161604

Max Phase: Preclinical

Molecular Formula: C14H15N5O5

Molecular Weight: 333.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(NCCCOc2ccc(C(=O)O)cc2)c(N=O)c(=O)[nH]1

Standard InChI:  InChI=1S/C14H15N5O5/c15-14-17-11(10(19-23)12(20)18-14)16-6-1-7-24-9-4-2-8(3-5-9)13(21)22/h2-5H,1,6-7H2,(H,21,22)(H4,15,16,17,18,20)

Standard InChI Key:  DEMFGJNJURCTNT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 333.30

Molecular Weight (Monoisotopic): 333.1073

AlogP: 1.33

#Rotatable Bonds: 8

Polar Surface Area: 159.76

Molecular Species: ACID

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.36

CX Basic pKa:

CX LogP: 0.21

CX LogD: -2.93

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.42

Np Likeness Score: -0.59

References

1. Lever OW, Bell LN, Hyman C, McGuire HM, Ferone R..  (1986)  Inhibitors of dihydropteroate synthase: substituent effects in the side-chain aromatic ring of 6-[[3-(aryloxy)propyl]amino]-5-nitrosoisocytosines and synthesis and inhibitory potency of bridged 5-nitrosoisocytosine-p-aminobenzoic acid analogues.,  29  (5): [PMID:3486292] [10.1021/jm00155a014]

2. Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG, Balakrishna K, White SW, Lee RE..  (2010)  Structural studies of pterin-based inhibitors of dihydropteroate synthase.,  53  (1): [PMID:19899766] [10.1021/jm900861d]

Source

Source(1):

• Scientific Literature